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Abstract Bruton’s tyrosine kinase (Btk) is considered an
essential signal transducer in B-cells. Mutational defects are
associated with a severe immunodeficiency syndrome, X-
chromosome linked agammaglobulinemia (XLA). Here we show
by coimmunoprecipitation that a member of the protein kinase C
(PKC) family, PKCW, is constitutively associated with Btk.
Neither antigen receptor (Ig) crosslinking nor stimulation of B-
cells with phorbol ester or H2O2 affected Btk/PKCW interaction.
GST precipitation analysis revealed association of the Btk
pleckstrin/Tec homology domain with PKCW. Transient over-
expression of PKCW deletion mutants as well as expression of
selected PKCW domains in 293T cells revealed that both the
kinase domain and the regulatory C1 region are independently
capable of binding to the Btk PH-TH domain. These data show
the existence of a PKCW/Btk complex in vivo and identify two
PKCW domains that participate in Btk interaction.
z 1999 Federation of European Biochemical Societies.
1. Introduction
During antigen receptor induced signal transduction of lym-
phocytes protein tyrosine kinases of the Src, Syk and Tec
family are considered to play essential roles [1,2]. Receptor
proximal signals are initiated via src kinase directed activation
of Syk and ZAP70 kinases followed by the activation of phos-
photyrosine/SH2 domain mediated signal cascades including
the phosphatidylinositol second messenger system and serine
kinases of the protein kinase C (PKC) family, which fuel
several downstream targets ¢nally leading to a proliferative
response of T- [1,3] and B-cells [2]. Tec kinases are expressed
in T- and B-cells and also in mast cells. Much attention has
been focused on one member, Bruton’s tyrosine kinase (Btk)
[4]. The Btk gene is variously mutated in X-linked immuno-
de¢cient mice (xid) or in X-linked agammaglobulinemia pa-
tients (XLA) [4,5]. These patients lack circulating B-cells and
immunoglobulins and are therefore very vulnerable to infec-
tious diseases [6]. Accordingly, Btk function is considered to
be associated with development and activation of B-cells e.g.
by controlling the PLCQ mediated intracellular Ca2 signalling
[7]. Within B-cell receptor triggered Btk activation, src kinases
and PI-3 kinase [8] are implicated. Aside from B-cell speci¢c
functions, Btk has been shown to be involved in FcORI in-
duced mast cell degranulation and cytokine production
through c-Jun N-terminal kinase (JNK) activation [9,10].
Btk contains a SH2, SH3, a Tec homology (TH) domain
and, within the amino terminal region, a pleckstrin homology
(PH) domain. This recently identi¢ed novel signal module [11]
was found to mediate membrane association via lipid binding
and, in addition, mediates protein-protein interactions [12].
For Btk, PH domain mediated PIP3 binding is essential for
activation leading to PLCQ tyrosine phosphorylation [8,13].
The importance of the PH domain as a regulator of Btk
function was shown by expression of a PH domain mutant
which leads to enhanced membrane association of Btk result-
ing in a transformed phenotype, suggestive of an upregulated
Btk function [14].
In the light of these data, studies reporting binding of the
PH domain of Btk to the regulatory C1 region of PKC [15,16]
are of interest. Binding of PKC has been mapped to the ami-
no terminal region of the PH domain of Btk [16] which is
considered to represent the lipid binding domain [17,18].
Both, phosphatidylinositol phosphates and PKC, have been
shown to bind with similar a⁄nities [19,16], providing an
example that PH domain mediated functions can be regulated
by both protein and lipid ligands. For Tec kinases, the phys-
iological function of PKC association appears to be the phos-
phorylation dependent regulation of Tec kinase activity
[20,15], pointing to a regulatory role of PKCs within Tec
kinase mediated signalling pathways.
We have recently described a novel PKC isotype, termed
PKCW [21], which, although ubiquitiously expressed, shows
particularly high expression in thymus and hematopoietic cells
[22]. In addition to the conserved kinase- and regulatory do-
mains in common to all PKC isoforms, PKCW displays struc-
tural features like a hydrophobic amino terminal domain, an
acidic regulatory domain [23] and a pleckstrin homology do-
main [11]. First evidence for involvement of PKCW in diverse
cellular functions stems from reports showing enhancement of
constitutive transport processes in PKCW overexpressing epi-
thelial cells [24] and PKCW activation during antigen receptor
mediated signalling in B-cells [25].
In the present study, we provide biochemical evidence that
PKCW is constitutively associated with Btk and show by in
vitro binding studies, that both the kinase domain and the
regulatory C1 domain of PKCW interact with Btk.
2. Materials and methods
2.1. Recombinant PKCW, construction of mutants and cell lines
The production of Sf158 insect cells overexpressing PKCW has been
described previously [26]. A cDNA fragment coding for the Btk pleck-
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strin homology domain including the TH domain [27] (amino acid 1^
174, Btk PH-TH) was ampli¢ed introducing an EcoRI and an XhoI
site. The cDNA fragment was cloned in frame with the glutathione S-
transferase (GST) in pGEX5X-3 and expressed as a bacterial fusion
protein. The human B-cell line SKW 6.4 was maintained in RPMI
1640 medium supplemented with 5% FCS. GST fusion proteins were
isolated according to the manufacturer’s instructions (Pharmacia). In
brief, fusion proteins were bound to glutathione sepharose and quan-
ti¢ed upon Coomassie staining by densitometric scanning, calibrated
against an albumin standard. The PKCW deletion mutant PKCWv1ÿ340
was constructed by deleting the respective cDNA region by restriction
enzyme digest, initiating translation at Met-340 as described [28].
PKCWvPH and PKCWvAD were created using a fusion PCR approach
looping out the coding region from K417^G553 (PKCWvPH) and
E336^D391 (PKCWvAD), respectively. Initial PCR to amplify the 5P-
cDNA fragment was carried out with a forward primer annealing at
nucleotide position 478 of the PKCW cDNA and a reverse primer
annealing at the 5P and 3P-end of the cDNA region to be looped
out. Ampli¢cation of the 3P-cDNA fragment was carried out using
a reverse primer annealing at nucleotide position 3000 of the PKCW
cDNA creating a BamH1 site and a forward primer annealing at the
5P- and 3P-end of the cDNA fragment to be looped out. Fusion PCR
generated a 2130-bp cDNA fragment for the vPH and a 2350-bp
cDNA fragment for the vAD mutant. PCR fragments were digested
with HindIII and BamH1 and used to replace the PKCW wild-type
cDNA fragment cloned in the expression vector pcDNA3 (Invitro-
gen). The presence of the deletions was veri¢ed by dideoxy sequencing
of both strands. The PKCW C1 region covering amino acids 1^327
and the kinase domain (amino acids 550^912 was PCR ampli¢ed add-
ing 5P-EcoRI and 3P-XbaI restriction sites and cloned in pCDNA3.
The construction of the kinase dead PKCW mutant (K612W) has been
described previously [29]. This mutant can be weakly immunoprecipi-
tated by the carboxyl terminal PKCW antibody. The R28P mutant of
the Btk PH domain cDNA (Btk-mut) was constructed by PCR based
mutagenesis exchanging Arg-28 (CGC) to Pro-28 (CCC) according to
the manufacturer’s instructions (Quick change site directed mutagen-
esis, Stratagene) and was veri¢ed by dideoxy sequencing. FLAG
tagged JNK cloned in pCDNA3 was used as a control for speci¢city
of GST Btk PH-TH domain precipitation.
2.2. Immunoprecipitation by antibodies and GST fusion protein
precipitation of PKCW
Cells were either left untreated or stimulated with phorbol ester
(100 nM, 10 min), Anti-IgG or H2O2/pervanadate as described [30]
before lysis at 4‡C in lysis bu¡er (20 mM Tris pH 7.4, 5 mM MgCl2,
1% Triton X-100, 1 mM Na-orthovanadate, 150 mM NaCl, 10 Wg/ml
leupeptin, 0.5 mM PMSF, 1 mM NaF, 1 mM nitrophenylphosphate)
by incubating 30 min. After centrifugation of cell debris (15 min,
15 000 rpm) GST precipitation was done in 1 ml lysate portions
(500 000 Sf 158 cells or 50U106 Jurkat cells) by incubation with the
indicated amounts of GST fusion proteins coupled to glutathione
sepharose for 90 min at 4‡C. For immunoprecipitation a PKCW anti-
body directed against carboxyl terminal epitopes and a Btk rabbit
antibody directed against amino terminal epitopes (both from Santa
Cruz Biotechnology) were used. Immunocomplexes were harvested by
incubation with protein G sepharose (Pharmacia, 30Wl/5U107 cell
equivalents) for 30 min at 4‡C. Immuno- or GST-complexes were
washed three times in lysis bu¡er and subjected to SDS-PAGE fol-
lowed by transfer to a nitrocellulose membrane. Western blot detec-
tion of PKCW and Btk was performed using either Btk or PKCW
antibodies as recommended by the manufacturer. GST was detected
using an anti-GST antibody (Pharmacia). Western blots were stained
using an alkaline phosphatase based detection system according to
standard conditions.
2.3. Generation of PKCW speci¢c antibodies
Puri¢ed PKCW, produced from Sf158 insect cells was used to im-
munize Balb/c mice. Using PKCW speci¢c immune serum and several
PKCW domain GST fusion proteins the antibody binding epitope
could be mapped within the amino terminal region (amino acids 1^
327). This mouse antiserum was used to immunoprecipitate the amino
terminal expressed PKCW domain in 293T cells.
2.4. Transfection of 293T cells
Two million cells were seeded per 90-mm-diameter dish in 10 ml
RPMI supplemented with 5% FCS and transfected with 10 Wg of
DNA and 50 Wl Superfect reagent (Qiagen) according to the manu-
facturer’s protocol. Cells were harvested 40 h upon transfection and
analyzed by GST pull down assays or immunoprecipitation as de-
scribed above.
3. Results and discussion
3.1. Btk associates with PKCW
Btk is expressed in B-cells and involved in early B-cell re-
ceptor initiated signalling pathways [31] in a similar way as
the tyrosine kinase Syk which has been reported to associate
with PKCW [25]. Therefore, we analyzed potential in vivo
association of PKCW and Btk by coimmunoprecipitation
from B-cells. SKW 6.4 B-cells were shown by Western blot
analyses to express PKCW and Btk in detectable amounts
(data not shown). Btk was immunoprecipitated from phorbol
ester stimulated or untreated SKW 6.4 cells using a rabbit
antibody directed against amino terminal epitopes (Fig. 1A,
lanes 1,2). In Btk immunoprecipitates, PKCW was hardly de-
tectable. However, Btk was readily detectable in PKCW im-
munoprecipitates from both, phorbol 12,13-dibutyrate (Pdbu)
stimulated and non-stimulated SKW 6.4 cells using two di¡er-
ent, PKCW speci¢c antibodies of rabbit and mouse origin,
directed against carboxyl terminal and amino terminal re-
gions, respectively (Fig. 1A, lanes 3,4,8,9). A previously noted
characteristic of the carboxyl terminal PKCW speci¢c antibody
is its weaker binding to Pdbu activated, compared to non-
activated PKCW [22], leading therefore to a reduced PKCW
detection and a slightly reduced Btk precipitation e⁄cacy
(Fig. 1A, lane 3 vs. 4). SKW 6.4 B-cells were either activated
with anti-IgG or the substitute stimulus, H2O2-pervanadate
[30], resulting in PKCW activation (data not shown) to mon-
itor potential changes in Btk association. However, no
changes in Btk association were found (Fig. 1A, lanes 5,6).
As a negative control, PKCW immunoprecipitates from Molt 4
cells, which do not express detectable amounts of Btk (data
not shown), but high amounts of PKCW, were analyzed. As
shown in Fig. 1A (lane 7), only the expected PKCW speci¢c
band was detectable, verifying the speci¢city of immunopreci-
pitation and Western blot reagents.
The PH domain of Btk has been reported to mediate asso-
ciation with PKCs in vitro and in vivo [15,16]. Further on it
has been shown that the region close to the PH domain, the
TH domain (Tec homology) [27], is essential for Btk structure
and function [32]. In order to identify whether this region is
critical for the Btk interaction with PKCW, we analyzed re-
combinant PKCW for potential Btk PH-TH domain associa-
tion. The Btk PH-TH domain was expressed as bacterial GST
fusion protein (see Section 2). Immobilized Btk PH-TH do-
main GST fusion protein was used to precipitate PKCW ex-
pressed in Sf158 cells. As shown in Fig. 1B, PKCW can be
detected by immunoblot analysis (upper panel) in precipitates
of GST fusion proteins with the Btk PH-TH domain. Using
di¡erent amounts of GST Btk PH-TH domain fusion protein,
PKCW can be readily detected with 1 Wg, showing best detec-
tion using 10 Wg of Btk PH-TH domain GST fusion proteins
(Fig. 1B). The speci¢city of PKCW binding to Btk PH-TH
domain was shown by pull down analysis of high amounts
of bacterial GST proteins producing no speci¢c PKCW immu-
noreactive signal (Fig. 1B, right lanes). Mutation of arginine-
28 in Btk either to histidine, proline or cysteine has been
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reported to be associated with the XLA or xid phenotype in
humans or mice [5], a¡ecting PKC interaction [15]. Therefore
we tested whether this mutation would a¡ect PKCW binding.
A GST Btk PH-TH domain fusion protein carrying the R28P
mutation indeed resulted in a decreased PKCW pull down
e⁄cacy (Figs. 1B and 3B). These ¢ndings are consistent
with previous observations [15] and point to a potential role
of PKCW in Btk mediated signalling pathways a¡ected in the
immunode¢ciency XLA phenotype. Using GST PH-TH do-
main fusion proteins of Btk, endogenous PKCW was similarly
precipitated from extracts of phorbol ester stimulated or non-
stimulated SKW 6.4 cells (data not shown).
3.2. The C1 region or the kinase domain of PKCW are su⁄cient
to mediate Btk PH-TH domain binding
The cysteine ¢ngers in the C1 region of PKCs have been
shown to represent the binding site for lipid second messen-
gers as well as for regulatory proteins a¡ecting protein kinase
activity [33,34]. The PH domain of Btk has been reported to
bind to the regulatory C1 domain of PKCO [16]. Although
considerably di¡erent in primary structure, the C1 region of
PKCW shares the typical consensus sequence of zinc ¢ngers
responsible for phorbol ester or second messenger binding.
We therefore used several PKCW deletion mutants lacking
the C1 region and other predicted functional domains to
map the binding site of the Btk PH-TH domain. Fig. 2A
displays the location of functional PKCW domains.
Transfection of the PKCW mutant PKCWv1ÿ340 lacking the
C1 region [35] in 293T cells resulted in the expression of an
approximately 70-kDa PKCW variant (wild-type 115 kDa) as
shown by Western blot analysis (Fig. 2B). Two further dele-
tions of PKCW domains considered to be involved in PKCW
regulation were constructed: deletion of the predicted PKCW
PH domain [11] (K417^G553, PKCWvPH) and of an acidic
region (E336^D391, PKCWvAD for acidic domain), the latter
of which is considered to participate in a phorbol ester inde-
pendent activation [23], results in expression of 90-kDa or
100-kDa PKCW mutants (Fig. 2B). A point mutation
(K612W), creating a kinase de¢cient mutant, was also em-
ployed.
Btk PH-TH domain GST fusion proteins were used to pre-
cipitate PKCW mutants from lysates of 293T cells transiently
transfected with the respective expression constructs. As
shown in Fig. 2C, PKCW could be readily detected in all
Btk precipitation analyses from 293T cells expressing wild-
type PKCW and PKCW mutants. In contrast to binding of
14-3-3 proteins to the regulatory region [35], kinase activityFig. 1. Btk is associated with PKCW. A: Btk coimmunoprecipitates
with PKCW. Shown are immunoprecipitates from lysates of 40U106
SKW 6.4 (lanes 1^6,8,9) or Molt 4 (lane 7) cells. Btk was immuno-
precipitated using an amino terminal rabbit antibody. PKCW was
immunoprecipitated using a rabbit antibody raised against carboxyl
terminal epitopes (lanes 3^7) or a mouse antiserum against amino
terminal PKCW regions (lanes 8,9). Detection was carried out with
the carboxyl terminal antiserum. Cells were either left unstimulated
or stimulated with phorbol ester (PdBu), anti-IgG or H2O2 as de-
scribed in Section 2. B: The Btk PH-TH domain associates with re-
combinant PKCW. PKCW expressed in Sf158 cells was precipitated
with the indicated amounts of Btk/Btk-mut GST PH-TH domain
fusion proteins or with GST protein as a control. Bound PKCW was
detected by immunoblot analysis using a PKCW antiserum and an
alkaline phosphatase coupled secondary antibody. GST (26 kDa) or
GST fusion proteins (40 kDa) were visualized using a goat anti-
GST antibody.
Fig. 2. Mapping of Btk binding domains in PKCW. A: Schematic
view of the known functional domains of PKCW. B: Expression of
PKCW mutants. 293T cells were transfected with the indicated
PKCW mutants and detected by Western blot analysis using a car-
boxyl terminal rabbit antibody. C: Determination of the Btk PH-
TH binding domain in PKCW. A GST Btk PH-TH domain fusion
protein was used to precipitate wild-type and the truncated PKCW
proteins upon transient overexpression in 293T cells. As a control
FLAG-tagged JNK was transfected and analyzed in parallel. Ex-
pression was monitored using an anti-FLAG monoclonal antibody.
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was not essential to precipitate PKCW by GST Btk PH-TH
domain fusion proteins. The kinase de¢cient PKCW mutant
PKCWK612W was precipitated with similar e⁄cacy like wild-
type PKCW (Fig. 2C, lower panel). FLAG-tagged JNK, which
was also expressed at a signi¢cant level, was not precipitated
and served as a control of speci¢city of GST Btk PH-TH pull
down assay (Fig. 2B and C, right lanes).
In contrast to previous data identifying the C1 domain of
phorbol ester responsive PKCs as the binding domain of the
Btk PH domain [16], our ¢ndings using GST PH-TH domain
fusion proteins point to a di¡erent association mode between
Btk and PKCW, involving its kinase domain too. To determine
in detail which region of PKCW mediates Btk PH-TH domain
binding, the PKCW C1 domain covering amino acids 1^327
including the cysteine rich zinc ¢nger like structure and the
kinase domain were expressed in 293T cells and analyzed for
potential Btk binding by precipitation assays (Fig. 3A). As
shown in Fig. 3B, the C1 region as well as the kinase domain
of PKCW could be precipitated by Btk GST PH-TH domain
fusion proteins. No speci¢c band was detectable by Western
blot analysis in GST Btk TH-PH precipitates from 293T cells
transfected with vector without insert (Fig. 3B, left lanes) or
with the Syk tyrosine kinase as an additional control for spe-
ci¢city (data not shown). These data as well as the ¢nding that
JNK could not be precipitated by GST Btk-mut PH-TH fu-
sion proteins (Fig. 2C) point to a speci¢c interaction of PKCW
domains with Btk. The R28P mutation known to a¡ect Btk
function and binding to PKCs was analyzed for potential
inhibition of PKCW association. As shown in Fig. 3B, the
R28P GST Btk PH-TH fusion protein did not signi¢cantly
a¡ect PKCW kinase domain binding whereas the R28P fusion
protein strongly reduces the precipitation e⁄cacy of the
PKCW C1 domain (Fig. 3B, right lane). According to these
data two independent binding sites of the Btk PH-TH domain
can be postulated in PKCW. These ¢ndings explain the partial
inhibition of GST Btk-mut PH-TH domain binding shown in
Fig. 1B, because only one of two binding sites is a¡ected. The
presence of two independent Btk PH-TH domain binding sites
provides an explanation for the ¢nding that in vitro precip-
itation of PKCW by GST Btk PH-TH is only weakly competed
by Pdbu containing phosphatidylserine micelles (data not
shown), similarly as shown for other PKCs [16].
Although Btk is physically associated with PKCW, the pre-
cise molecular mechanism of Btk PH-TH domain interaction
with PKCW and the physiological relevance of this interaction
is currently unknown. cPKC mediated phosphorylation of Btk
in vitro leads to reduced tyrosine autophosphorylation [15]
and therefore has been suggested to negatively regulate Btk
activity. Immunoprecipitates of Btk as well as GST PH-TH
domain fusion proteins are no substrates for in vitro phos-
phorylation by recombinant PKCW (F.J.J., unpublished obser-
vations) suggesting that PKCW alone is not su⁄cient for ef-
fective serine phosphorylation of Btk. Vice versa, PKCW is not
considered as a substrate for Btk, as there is no signi¢cant
tyrosine phosphorylation upon cellular stimulation (F.J.J., un-
published observations). As our data indicate no direct in
vitro phosphorylation of either PKCW or Btk, association
mediated regulation of PKCW and/or Btk kinase activity in
vivo might be dependent on the presence of additional, cur-
rently unknown factors. Alternatively, PKCW might serve as a
sca¡old protein generating a Btk activating signal complex. In
favor of this hypothesis are the ¢ndings that the C1 domain of
PKCW serves as binding region for phosphatidylinositol 4-ki-
nase and a phosphatidylinositol 4-phosphate 5-kinase [28]
producing phosphatidylinositol phosphates which are in-
volved in Btk membrane translocation which is a prerequisite
for activation. Such a model would predict that the amino
terminal region of Btk mediates PKCW C1 domain associa-
tion, whereas carboxyl terminal epitopes of the Btk PH-TH
domain are responsible for constitutive association with the
PKCW kinase domain.
In B-lymphocytes, PKCW is associated with the initial B-cell
receptor signalling complex together with PLCQ1/2 and the
tyrosine kinase Syk upon IgM stimulation [25]. As Btk is
essential for PLCQ2 activation [36] a participation of Syk,
Btk and PKCW in the regulation of PLCQ triggered signalling
pathways is conceivable. The role of PKCW in the cellular
signalling complex as a potential negative regulator of PLCQ
[25] or regulator of Btk will be a subject to further research
activities.
The demonstration of in vitro association of PKCW with
Btk points to a role in receptor proximal signalling events
of lymphocyte antigen receptors. As, in addition to PKCW,
several other PKC isotypes also associate with Btk [16], they
might be components of a partially redundant signalling sys-
tem. This is underlined by the in vivo phenotype of the PKCM
knock-out mouse, showing a similar, but milder immunode¢-
ciency syndrome as compared to the Btk defective xid mouse
[6,37]. It is therefore possible that the defects in signal trans-
duction pathways involving PKCM are compensated in the
PKCL knock out mouse by other lymphocyte expressed
PKC isotypes, probably including PKCW.
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Fig. 3. BTK PH-TH GST fusion proteins bind to the kinase do-
main and the regulatory C1 region of PKCW. A: Expression of
PKCW domains. The PKCW kinase domain and the amino terminal
region were transiently expressed in 293T cells. The kinase domain
was detected using a carboxyl terminal antibody, the C1 domain
with a polyclonal mouse antiserum. B: GST Btk PH-TH fusion pro-
teins bind speci¢c to the kinase domain and the regulatory region
of PKCW. Shown are precipitation analyses using the wild-type Btk
PH-TH GST domain fusion protein (PH) or Btk carrying the R28P
mutation (PH-mut). PKCW was detected using a mix of the domain
speci¢c antibodies. As a control for speci¢city GST precipitations
were included (data not shown).
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